IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
4
Neutral
8
Bullish
2
Bearish
19
Neutral
12
Bullish
15
Bearish
15
Neutral
4
Bullish
13
Bearish
15
Neutral
4
Bullish
13
Bearish
15
Neutral
4
Bullish
13
Bearish
15
Neutral
4
Bullish
13
Upcoming Result Date: Today
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Dhanvantri Jeevan Rekha Ltd (ZDHJERK) is currently trading at 22.03 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Dhanvantri Jeevan Rekha Limited operates Dhanvantri Hospital, a multi‑speciality diagnostic and therapeutic hospital in Meerut providing outpatient, inpatient, ICU and advanced procedure services including MRI and a fully operational Cath Lab for angiography and angioplasty, specialising in cardiology, urology, neurology and orthopedics with cashless hospitalisation tie‑ups for accredited patients. For the quarter ended 30 June 2026 the company reported standalone revenue of approximately ₹780 lakh, total expenses of around ₹769 lakh and a reported profit of about ₹18 lakh, implying a narrow operating margin near 2–3%; reported basic/diluted EPS for the period was stated at approximately ₹0.44 on ₹10 face value shares. The hospital positions itself as one of the earlier comprehensive tertiary care centres in Western Uttar Pradesh, emphasising continuous equipment upgrades, a multidisciplinary ICU, higher‑end cardiac interventions and patient‑oriented services at moderate pricing, which supports steady local demand from Meerut and surrounding districts rather than large metropolitan referral flows. Corporate governance and disclosure activity: Board approved the unaudited quarterly results on 13 August 2026, statutory auditors completed a limited review with no material exceptions reported, and the company indicated publication of results and an Annual General Meeting date; filings demonstrate regulatory compliance but also highlight the company’s small scale and modest profitability profile.
Over the past 52 weeks, Dhanvantri Jeevan Rekha Ltd has traded between a low of ₹19.53 and a high of ₹30.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Dhanvantri Jeevan Rekha Ltd has a market capitalization of approximately 8.60. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Dhanvantri Jeevan Rekha Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 16.86 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 8.60 Cr, Dhanvantri Jeevan Rekha Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Dhanvantri Jeevan Rekha Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Dhanvantri Jeevan Rekha Ltd is 16.86. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Dhanvantri Jeevan Rekha Limited operates Dhanvantri Hospital, a multi‑speciality diagnostic and therapeutic hospital in Meerut providing outpatient, inpatient, ICU and advanced procedure services including MRI and a fully operational Cath Lab for angiography and angioplasty, specialising in cardiology, urology, neurology and orthopedics with cashless hospitalisation tie‑ups for accredited patients.
For the quarter ended 30 June 2026 the company reported standalone revenue of approximately ₹780 lakh, total expenses of around ₹769 lakh and a reported profit of about ₹18 lakh, implying a narrow operating margin near 2–3%; reported basic/diluted EPS for the period was stated at approximately ₹0.44 on ₹10 face value shares.
The hospital positions itself as one of the earlier comprehensive tertiary care centres in Western Uttar Pradesh, emphasising continuous equipment upgrades, a multidisciplinary ICU, higher‑end cardiac interventions and patient‑oriented services at moderate pricing, which supports steady local demand from Meerut and surrounding districts rather than large metropolitan referral flows.
Corporate governance and disclosure activity: Board approved the unaudited quarterly results on 13 August 2026, statutory auditors completed a limited review with no material exceptions reported, and the company indicated publication of results and an Annual General Meeting date; filings demonstrate regulatory compliance but also highlight the company’s small scale and modest profitability profile.
Healthcare Services
Healthcare Service Provider
9 Cr
Low Risk
17.7
59.6
0.7
0.8
30.00
19.53
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1.96 | 11 Cr | -1.26 | 1.12 | 0.00 | -46.60 | -27.58 | -19.52 | ||
20.99 | 9 Cr | 16.86 | 0.82 | 0.00 | 3.81 | 3.58 | 2.90 | ||
11.93 | 8 Cr | -14.40 | 0.00 | 0.00 | -10.91 | 0.16 | -7.87 | ||
30.00 | 7 Cr | 16.31 | 0.74 | 0.00 | 4.52 | 6.80 | 3.67 | ||
6.60 | 6 Cr | 81.43 | 0.40 | 0.00 | 0.45 | 0.71 | 0.40 | ||
4.73 | 6 Cr | -56.80 | 0.51 | 0.00 | -1.16 | 0.77 | -0.67 | ||
4.32 | 4 Cr | -4.66 | 0.24 | 0.00 | -3.76 | -1.02 | -2.81 | ||
| Median: 7 Co. | — | 6.60 | 7 Cr | -1.26 | 0.51 | 0.00 | -1.16 | 0.71 | -0.67 |
